Shopping Cart 0
Cart Subtotal
AED 0

Kura Oncology Inc (KURA) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 1101

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 2202

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 3303

Details

Summary

Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company's lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer, including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigative drug candidate for mitogen-activated protein kinase pathway tumors; and KO-539, a small molecule inhibitor for the treatment of acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

Kura Oncology Inc Key Recent Developments

Mar 05,2019: Kura Oncology reports fourth quarter and full year 2018 financial results

Dec 02,2018: Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

Nov 28,2018: Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Nov 08,2018: Kura Oncology adds commercial veteran Mary Szela to Board of Directors

Nov 05,2018: Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

This comprehensive SWOT profile of Kura Oncology Inc provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Kura Oncology Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

READ MORE

Table Of Content

Scope

Table of Contents

Section 1-About the Company

Kura Oncology Inc-Key Information

Kura Oncology Inc-Overview

Kura Oncology Inc-Key Employees

Kura Oncology Inc-Key Employee Biographies

Kura Oncology Inc-Key Operational Heads

Kura Oncology Inc-Major Products and Services

Kura Oncology Inc-History

Kura Oncology Inc-Company Statement

Kura Oncology Inc-Locations And Subsidiaries

Kura Oncology Inc-Key Manufacturing facilities

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Kura Oncology Inc-Business Description

Kura Oncology Inc-Corporate Strategy

Kura Oncology Inc-SWOT Analysis

SWOT Analysis-Overview

Kura Oncology Inc-Strengths

Kura Oncology Inc-Weaknesses

Kura Oncology Inc-Opportunities

Kura Oncology Inc-Threats

Kura Oncology Inc-Key Competitors

Section 3-Company Financial Performance Charts

Kura Oncology Inc-Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Appendix

Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Note*: Some sections may be missing if data is unavailable for the company


List Of Figure

List of Figures

Kura Oncology Inc, Performance Chart

Kura Oncology Inc, Ratio Charts


List Of Table

List of Tables

Kura Oncology Inc, Key Information

Kura Oncology Inc, Key Ratios

Kura Oncology Inc, Share Data

Kura Oncology Inc, Major Products and Services

Kura Oncology Inc, History

Kura Oncology Inc, Key Employees

Kura Oncology Inc, Key Employee Biographies

Kura Oncology Inc, Key Operational Heads

Kura Oncology Inc, Other Locations

Kura Oncology Inc, Subsidiaries

Kura Oncology Inc, Key Manufacturing facilities

Kura Oncology Inc, Key Competitors

Kura Oncology Inc, SWOT Analysis

Kura Oncology Inc, Ratios based on current share price

Kura Oncology Inc, Annual Ratios

Kura Oncology Inc, Interim Ratios

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Kura Oncology Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

Company Profile

Company Profile Title

Summary

Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company's lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer, including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigative drug candidate for mitogen-activated protein kinase pathway tumors; and KO-539, a small molecule inhibitor for the treatment of acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

Kura Oncology Inc Key Recent Developments

Mar 05,2019: Kura Oncology reports fourth quarter and full year 2018 financial results

Dec 02,2018: Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

Nov 28,2018: Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Nov 08,2018: Kura Oncology adds commercial veteran Mary Szela to Board of Directors

Nov 05,2018: Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

This comprehensive SWOT profile of Kura Oncology Inc provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Kura Oncology Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

READ MORE

Scope

Table of Contents

Section 1-About the Company

Kura Oncology Inc-Key Information

Kura Oncology Inc-Overview

Kura Oncology Inc-Key Employees

Kura Oncology Inc-Key Employee Biographies

Kura Oncology Inc-Key Operational Heads

Kura Oncology Inc-Major Products and Services

Kura Oncology Inc-History

Kura Oncology Inc-Company Statement

Kura Oncology Inc-Locations And Subsidiaries

Kura Oncology Inc-Key Manufacturing facilities

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Kura Oncology Inc-Business Description

Kura Oncology Inc-Corporate Strategy

Kura Oncology Inc-SWOT Analysis

SWOT Analysis-Overview

Kura Oncology Inc-Strengths

Kura Oncology Inc-Weaknesses

Kura Oncology Inc-Opportunities

Kura Oncology Inc-Threats

Kura Oncology Inc-Key Competitors

Section 3-Company Financial Performance Charts

Kura Oncology Inc-Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Appendix

Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Note*: Some sections may be missing if data is unavailable for the company


List Of Figure

List of Figures

Kura Oncology Inc, Performance Chart

Kura Oncology Inc, Ratio Charts


List Of Table

List of Tables

Kura Oncology Inc, Key Information

Kura Oncology Inc, Key Ratios

Kura Oncology Inc, Share Data

Kura Oncology Inc, Major Products and Services

Kura Oncology Inc, History

Kura Oncology Inc, Key Employees

Kura Oncology Inc, Key Employee Biographies

Kura Oncology Inc, Key Operational Heads

Kura Oncology Inc, Other Locations

Kura Oncology Inc, Subsidiaries

Kura Oncology Inc, Key Manufacturing facilities

Kura Oncology Inc, Key Competitors

Kura Oncology Inc, SWOT Analysis

Kura Oncology Inc, Ratios based on current share price

Kura Oncology Inc, Annual Ratios

Kura Oncology Inc, Interim Ratios

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Kura Oncology Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts